Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy

作者：Morato Laia; Galino Jorge; Ruiz Montserrat; Calingasan Noel Ylagan; Starkov Anatoly A; Dumont Magali; Naudi Alba; Jose Martinez Juan; Aubourg Patrick; Portero Otin Manuel; Pamplona Reinald; Galea Elena; Beal M Flint; Ferrer Isidre; Fourcade Stephane; Pujol Aurora^*

来源：Brain, 2013, 136(8): 2432-2443.

DOI：10.1093/brain/awt143

• mitochondrial biogenesis
• oxidative stress
• axonal degeneration
• pioglitazone
• X-linked adrenoleukodystrophy

X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids. In mice, ABCD1 loss causes late onset axonal degeneration in the spinal cord in association with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. Increasing evidence indicates that oxidative stress and bioenergetic failure play major roles in the pathogenesis of X-linked adrenoleukodystrophy. In this study, we aimed to evaluate whether mitochondrial biogenesis is affected in X-linked adrenoleukodystrophy. We demonstrated that Abcd1 null mice show reduced mitochondrial DNA concomitant with downregulation of mitochondrial biogenesis pathway driven by PGC-1 alpha/PPAR gamma and reduced expression of mitochondrial proteins cytochrome c, NDUFB8 and VDAC. Moreover, we show that the oral administration of pioglitazone, an agonist of PPAR gamma, restored mitochondrial content and expression of master regulators of biogenesis, neutralized oxidative damage to proteins and DNA, and reversed bioenergetic failure in terms of ATP levels, NAD(+)/NADH ratios, pyruvate kinase and glutathione reductase activities. Most importantly, the treatment halted locomotor disability and axonal damage in X-linked adrenoleukodystrophy mice. These results lend support to the use of pioglitazone in clinical trials with patients with adrenomyeloneuropathy and reveal novel molecular mechanisms of action of pioglitazone in neurodegeneration. Future studies should address the effects of this anti-diabetic drug on other axonopathies in which oxidative stress and mitochondrial dysfunction are contributing factors.

• 出版日期2013-8